Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00748579 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of the Effect of CK-1827452 Injection on Myocardial Efficiency
A Phase 2 study, sponsored by Cytokinetics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT00748579 is a Phase 2 study that was terminated before completion, run by Cytokinetics. The registered enrollment target is 2 participants.
The verdict
NCT00748579, a Phase 2 study, was terminated before completion, sponsored by Cytokinetics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
The purpose for this study (CY 1124) is to evaluate the effects of CK-1827452, a cardiac myosin activator, on myocardial systolic performance, myocardial oxygen consumption, and myocardial efficiency in patients with heart failure and to confirm that the unique preclinical pharmacological profile of CK- 1827452 is substantially the same in patients with heart failure.
Interventions
- DRUG CK-1827452
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2008-09 |
| Est. Completion | 2009-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00748579
The ClinicalTrials.gov registry entry for NCT00748579 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cytokinetics, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CK-1827452 is the first listed.
NCT00748579 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00748579 about?
NCT00748579 is a clinical study titled "Phase II Study of the Effect of CK-1827452 Injection on Myocardial Efficiency". The purpose for this study (CY 1124) is to evaluate the effects of CK-1827452, a cardiac myosin activator, on myocardial systolic performance, myocardial oxygen consumption, and myocardial efficiency in patients with heart failure and to confirm that the unique preclinical pharmacological profile of...
What is the current status of trial NCT00748579?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2008-09. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00748579?
The interventions under investigation include: CK-1827452 (DRUG).
Who is sponsoring clinical trial NCT00748579?
This trial is sponsored by Cytokinetics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.